Newswire (Published: Tuesday, January 9, 2018, Received: Friday, January 5, 2018, 12:13:34 PM CST)

Word Count: 489

New Findings on Prostate Cancer Discussed by Researchers at University of Helsinki and Helsinki University Hospital (Repeat multiparametric MRI in prostate cancer patients on active surveillance)

By a News Reporter-Staff News Editor at Cancer Weekly -- A new study on Oncology - Prostate Cancer is now available. According to news reporting originating in Helsinki, Finland, by NewsRx journalists, research stated, "This study was conducted to describe the changes in repeat multiparametric MRI (mpMRI) occurring in prostate cancer (PCa) patients during active surveillance (AS), and to study possible associations between mpMRI-related parameters in predicting prostate biopsy (Bx) Gleason score (GS) upgrading >3+3 and protocol-based treatment change (TC). The study cohort consisted of 76 AS patients with GS 3+3 PCa and at least two consecutive mpMRIs of the prostate performed between 2006-2015."

The news reporters obtained a quote from the research from the University of Helsinki and Helsinki University Hospital, "Patients were followed according to the Prostate Cancer Research International Active Surveillance (PRIAS) protocol and an additional mpMRI. The primary end points were GS upgrading (GU) (>3+3) in protocol-based Bxs and protocol-based TC. Out of 76 patients, 53 (69%) had progression (PIRADS upgrade, size increase or new lesion[s]), while 18 (24%) had radiologically stable disease, and 5 (7%) had regression (PIRADS or size decrease, disappearance of lesion[s]) in repeat mpMRIs during AS. PIRADS scores of 4-5 in the initial mpMRI were associated with GU (p=0.008) and protocol-based TC (p=0.009). Tumour progression on repeat mpMRIs was associated with TC (p=0.045) but not with GU (p=1.00)."

According to the news reporters, the research concluded: "PIRADS scores of 4-5 predict GU (sensitivity 0.80 [95% confidence interval (CI); 0.51-0.95, specificity 0.62 [95% CI; 0.52-0.77]) with PPV and NPV values of 0.34 (95% CI; 0.21-0.55) and 0.93 (95% CI; 0.80-0.98), respectively. mpMRI is a useful tool not only to select but also to monitor PCa patients on AS."

For more information on this research see: Repeat multiparametric MRI in prostate cancer patients on active surveillance. Plos One, 2017;12(12):e0189272. (Public Library of Science - www.plos.org; Plos One - www.plosone.org)

Our news correspondents report that additional information may be obtained by contacting J.T. Eineluoto, Dept. of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Additional authors for this research include P. Jarvinen, A. Kenttamies, T.P. Kilpelainen, H. Vasarainen, K. Sandeman, A. Erickson, T. Mirtti and A. Rannikko (see also Oncology - Prostate Cancer).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1371/journal.pone.0189272. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Europe, Finland, Helsinki, Oncology, Epidemiology, Prostate Cancer, Health and Medicine, Prostatic Neoplasms.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

Companies

Public Library of Science

Industries

Healthcare
      Healthcare Facilities
            Hospitals

Places

Northern Europe
Finland
Europe
Helsinki

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Medical Specialties and Practices
            Urology